Last month, however, the First Circuit came more in line with the majority view. In In re Asacol Antitrust Litigation, the court reversed certification of a consumer class that included a significant number (approximately 10 percent) of uninjured persons. In Asacol, the defendant manufacturer of a drug used to treat ulcerative colitis was accused of violating the Sherman Act by pulling Asacol from the market shortly before the drug's patent was set to expire and replacing it with two similar, patent-protected drugs. The theory of liability was that by prematurely pulling Asacol from the market, the defendant had precluded entry of lower-cost, generic alternatives in the treatment of ulcerative colitis. The plaintiff class in Asacol comprised consumers who had purchased Asacol before it was taken off the market and who then had purchased at least one of the two replacement drugs after Asacol was taken off the market.